On Wednesday, Boston Scientific Corporation BSX reported fourth-quarter revenues of $4.56 billion, beating the consensus estimate of $4.424 billion.

Sales increased 22.4% on a reported basis, compared to the company’s guidance range of 16.5%-18.5%, and 23.1% on an operational basis, 19.5% on an organic basis, compared to the company’s guidance range of 14%-16%.

The company earned an adjusted EPS of 70 cents, beating the consensus of 66 cents and the management guidance of $0.64-$0.66.

“2024 was one of the best years in the history of Boston Scientific, fueled by our innovative portfolio, the launch of our FARAPULSE Pulsed Field Ablation System, as well as significant clinical achievements and commercial excellence across businesses and regions,” said Mike Mahoney, chairman and chief executive officer of Boston Scientific.

The company’s cardiovascular segment generated sales of $2.94 billion, rising 28.8% (29.5% operationally and 27.4% organically).

• Boston Scientific reported 31.1% growth in cardiology products and 21% in peripheral interventions.

Also Read: Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal

MedSurg segment revenues increased 12.4% to $1.62 billion (13% operationally and 7% organically).

• Urology led the way with a 19.5% increase. Neuromodulation (+11.4%) and Endoscopy (7%) followed.

Outlook: Boston Scientific forecasts net sales growth of approximately 12.5%-14.5% in 2025 on a reported basis and approximately 10%-12% on an organic basis.

The company estimates 2025 adjusted EPS $2.80-$2.87 compared to consensus of $2.81.

The company estimates net sales growth for the first quarter of 2025 of approximately 17%-19% on a reported basis and approximately 14%-16% on an organic basis, with adjusted EPS of $0.66-$0.68 compared to consensus of $0.64.

Price Action: BSX stock is up 0.84% at $104.41 during the premarket session at last check Wednesday.

Read Next:

• Tyson Foods Stock Trading Around Fair Value, Analyst Upgrades Stock To Neutral